News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

AstraZeneca PLC (AZN) Boasts Of Pipeline But Analysts Still Believe Deals Are A Must


2/6/2014 9:52:31 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

AstraZeneca Plc (AZN), the U.K.’s second-biggest drugmaker, is advancing experimental drugs into late-stage clinical trials faster than expected in a bid to replace sales that it’s losing to generic competitors. Three medicines that may move into final-stage development this year have potential for peak annual sales of at least $1 billion, the London-based company said yesterday. One of those is an Alzheimer’s drug called AZD3293 that’s in early-stage testing, meaning it could skip the middle stage of human trials.

Help employers find you! Check out all the jobs and post your resume.

Read at BusinessWeek


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES